Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
- Biotest exercises its option and receives exclusive rights for haemophilia on the use of Affibody's Albumod(TM) technology designed to prolong the half life of biopharmaceuticals
- Preclinical results suggest a high probability of success for improving properties of innovative new biopharmaceuticals in haemophilia
Dreieich, 4 December 2018. Biotest AG today announces to have finalized the research phase of the research license and option agreement signed in 2015 and decided to exercise its option. Biotest will receive exclusive rights for further development and commercialization of its innovative new haemophilia product.
"Preclinical results so far with the Albumod(TM) technology are very promising and we believe in its potential for the development of improved protein drugs in Biotest's therapeutic areas such as haemophilia" says Dr Jörg Schüttrumpf, Senior Vice President Global Research Biotest.
Affibody will receive a license conversion fee and milestone payments as well as royalties.
As a lifelong inherited bleeding disorder, haemophilia affects about 1 in 10,000 people worldwide. With estimated USD 11 billion in 2024, the global FVIII/FIX market is substantial and grows with a compound annual growth rate (CAGR) of around 1.8%. Haemophilia is one of a number of such disorders that prevent blood from clotting properly. People with haemophilia experience prolonged internal bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability while bleeding into major organs, such as the brain, can cause death. For more information on haemophilia, please visit the World Federation of Haemophilia website at http://www.wfh.org/en/page.aspx?pid=646
About the AlbumodTM platform
Affibody's AlbumodTM technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, thereby allowing for less frequent dosing and less fluctuations of concentrations in blood. In addition to these patient benefits, the overall treatment costs could be reduced. For more information please refer to: www.affibody.se.
About Affibody AB
Affibody AB is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody(R) molecules and AlbumodTM. Affibody is developing a portfolio of innovative drug projects and in addition, offers the half-life extension technology, AlbumodTM for outlicensing.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
04.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de